Fig. 1a



CSF-1
GM-CSF
120%
100%
80%
60%
40%
20%
0%
% cell viability
00,000
00,001
00,010
00,100
01,000
10,000
conc. of hMab 2F11-e7 [µg/ml]

Fig. 1b




Fig. 2a



CSF-1 ELISA - Cyno Plasma Batch 1
(0.1 mg/kg anti-CSF1R hMab 2F11-e7)-Animal 1
M-CSF (pg/ml)
16000
14000
12000
10000
8000
6000
4000
2000
0
Pre-Dose
2 hr
24 hr
48 hr
72 hr
96 hr
168 hr
d15
d22
Time Point

Fig. 2b



CSF-1 ELISA - Cyno Plasma Batch 1
(1 mg/kg anti-CSF1R hMab 2F11-e7)-Animal 1
M-CSF (pg/ml)
16000
14000
12000
10000
8000
6000
4000
2000
0
Pre-Dose
2 hr
24 hr
48 hr
72 hr
96 hr
168 hr
d15
d22
Time Point

Fig. 2c



CSF-1 ELISA - Cyno Plasma Batch 1
(10 mg/kg anti-CSF1R hMab 2F11-e7)-Animal 1
M-CSF (pg/ml)
16000
14000
12000
10000
8000
6000
4000
2000
0
Pre-Dose
2 hr
24 hr
48 hr
72 hr
96 hr
168 hr
d15
d22
Time Point

Fig. 2d



CSF-1 ELISA - Cyno Plasma Batch 1
(100 mg/kg anti-CSF1R hMab 2F11-e7)-Animal 1
M-CSF (pg/ml)
16000
14000
12000
10000
8000
6000
4000
2000
0
Pre-Dose
2 hr
24 hr
48 hr
72 hr
96 hr
168 hr
d15
d22
Time Point

Fig. 3



+ αCD3/αCD28
w/o Mφ
1:16
1:4
1:1
1:1
+ Mφ
unst
proliferating cells x 10³
0
10
20
30

Fig. 4




<mouse CSF1R>
<PD-L1>
<mouse CSF1R> /<PD-L1>
Control (Mouse IgG1)
Progression > 700 mm³
Study day
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
20
30
40
50

Fig. 5


Progression > 700 mm³
Study day
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
0
10
20
30
40
50
60
70
80
<mouse CSF1R>
<mouse CSF1R> / <PD-L1>
<PD-L1>
Control (Mouse IgG1)

9 / 9